血小板活化因子乙酰水解酶升高在乙型肝炎患者中的临床应用

Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.

作者信息

Feng Limin, Zhao Ying, Feng Guofang, Chen Yu

机构信息

Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

出版信息

Lipids Health Dis. 2014 Jun 28;13:105. doi: 10.1186/1476-511X-13-105.

DOI:10.1186/1476-511X-13-105

PMID:24973921

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4096520/

Abstract

BACKGROUND

The aim of this study was to investigate the variation of platelet-activating factor acetylhydrolase (PAF-AH) in patients with various stages of hepatitis B infection and evaluate the association between PAF-AH activity and chronic severe hepatitis B (CSHB) and mortality in patients with hepatitis B.

METHODS

Serum PAF-AH activity was measured in 216 patients with hepatitis B and in 152 healthy controls using an automatic biochemical analysis system. Spearman correlation was used to investigate the correlation between PAF-AH activity and other biochemical indicators. The receiver operating characteristic (ROC) curve and multivariable logistic regression analysis were used to evaluate the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B.

RESULTS

The PAF-AH activities in patients with CSHB (1320 ± 481 U/L) were significantly higher than those in healthy controls and in other hepatitis B groups (all P<0.01). In patients with hepatitis B, PAF-AH activity correlated with total bilirubin (r=0.633), total bile acid (r=0.559), aspartate aminotransferase (r=0.332), apolipoprotein B (r=0.348), high-density lipoprotein cholesterol (r=-0.493), and apolipoprotein AI (r=-0.530). The areas under the ROC curves for the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B were 0.881 (95% confidence interval (CI): 0.824-0.937, P<0.001) and 0.757 (95% CI: 0.677-0.837, P<0.001), respectively. Multivariate logistic regression analysis showed PAF-AH activity to be an independent factor predicting CSHB with an odds ratio of 1.003 (95% CI: 1.002-1.005, P<0.001).

CONCLUSION

Elevated PAF-AH in patients with hepatitis B was significantly associated with liver damage. Thus, serum PAF-AH could be used as a novel indicator for predicting CSHB and mortality in patients with hepatitis B. Further, PAF-AH activity was an independent factor predicting CSHB.

摘要

背景

本研究旨在调查不同阶段乙型肝炎感染患者血小板活化因子乙酰水解酶（PAF-AH）的变化，并评估PAF-AH活性与慢性重型乙型肝炎（CSHB）及乙型肝炎患者死亡率之间的关联。

方法

使用自动生化分析系统测定216例乙型肝炎患者和152例健康对照者的血清PAF-AH活性。采用Spearman相关性分析PAF-AH活性与其他生化指标之间的相关性。使用受试者工作特征（ROC）曲线和多变量逻辑回归分析评估PAF-AH活性预测乙型肝炎患者CSHB和死亡率的能力。

结果

CSHB患者的PAF-AH活性（1320±481 U/L）显著高于健康对照者及其他乙型肝炎组（均P<0.01）。在乙型肝炎患者中，PAF-AH活性与总胆红素（r=0.633）、总胆汁酸（r=0.559）、天冬氨酸转氨酶（r=0.332）、载脂蛋白B（r=0.348）、高密度脂蛋白胆固醇（r=-0.493）和载脂蛋白AI（r=-0.530）相关。PAF-AH活性预测乙型肝炎患者CSHB和死亡率的ROC曲线下面积分别为0.881（95%置信区间（CI）：0.824-0.937，P<0.001）和0.757（95%CI：0.677-0.837，P<0.001）。多变量逻辑回归分析显示，PAF-AH活性是预测CSHB的独立因素，比值比为1.003（95%CI：1.002-1.005，P<0.001）。